

### **CDC73 Mutations:**

*CDC73*-related conditions include familial isolated hyperparathyroidism (FIHP), parathyroid carcinoma, and hyperparathyroidism-jaw tumor (HPT-JT) syndrome.<sup>1,2</sup> Not everyone with a *CDC73* mutation will manifest symptoms, but up to 90% will develop a *CDC73*-related condition.

FIHP and hereditary parathyroid carcinoma do not involve other organs. However, HPT-JT is typically a multi-system neoplastic condition. Features include primary hyperparathyroidism due to parathyroid adenoma or carcinoma, ossifying fibroma(s) of the maxilla and/or mandible, renal lesions including cysts, hamartomas, and possibly Wilms tumor.<sup>2</sup>

In HPT-JT, the onset of primary hyperparathyroidism (PHPT) typically occurs in adolescence or early adulthood; 95% of cases will develop PHPT.<sup>3,4</sup>

- The risk of parathyroid carcinoma is 10-15%.<sup>3</sup>
- Approximately 20% of affected individuals develop renal cysts, hamartomas, and possibly Wilms tumor; however, the lifetime risk of kidney cancer is currently unclear.<sup>3</sup>
- The risks of ossifying jaw fibromas is 30-40%.<sup>3</sup>
- Benign and malignant uterine tumors appear to be common in women with HPT-JT syndrome.<sup>5</sup>

### *Management Recommendations*

There are no established screening or surveillance guidelines for individuals with a pathogenic *CDC73* variant, but the following have been suggested to establish the extent of disease in an individual diagnosed with a *CDC73*-related disorder.<sup>3,4</sup>

- Evaluation for primary hyperparathyroidism: measurement of intact parathyroid hormone and serum calcium concentration
- Baseline bone density of the lumbar spine, hips, and distal radius by dual-energy x-ray absorptiometry (DXA) and 24-hour urine collection for calcium in individuals with evidence of primary hyperparathyroidism
- Evaluation for jaw tumors: panoramic jaw x-ray with neck shielding
- Evaluation for renal lesions: renal ultrasound examination preferred; CT and/or MRI as clinically indicated
- Evaluation for uterine tumors in women starting at reproductive age: pelvic examination as part of routine gynecologic care; pelvic ultrasound examination in any woman with a menstrual disorder with further imaging studies (CT and/or MRI) as clinically indicated

The following surveillance guidelines have been proposed:<sup>3</sup>

- Annual serum calcium, iPTH, and 25-(OH) vitamin D (to evaluate for possible coexisting vitamin D deficiency as a cause of elevated iPTH levels or unexpectedly "normal" calcium concentrations), starting at age 5.
- In patients with a history of parathyroid carcinoma who develop a rise in calcium levels, consider the possibility of a new primary parathyroid tumor in addition to recurrence/progression of malignant disease.
- Consider periodic parathyroid ultrasound examination for the detection of non-functioning parathyroid carcinoma, which has developed on rare occasion.
- Obtain panoramic x-ray dental imaging with neck shielding at least every five years. Dental providers should be notified of the presence of a *CDC73*-related disorder and the need for monitoring for osseous fibromas of the maxilla and mandible.
- Monitor for kidney lesions by renal ultrasound examination at least every five years, starting at the age of diagnosis.
  - Serum creatinine concentrations should be monitored in those individuals with renal cysts.
  - Individuals with solid lesions should be referred for appropriate subspecialty care.

- Starting at reproductive age, women with a *CDC73*-related disorder should undergo regular gynecologic care (including pelvic examination).
  - Care providers in obstetrics and gynecology should be notified of the risk of uterine tumors
  - Pelvic ultrasound examination should be obtained for any woman with a menstrual disorder (particularly abnormal uterine bleeding or menorrhagia), with further imaging studies (CT or MRI) as clinically indicated.

In addition, it is recommended that individuals with *CDC73*-related conditions avoid dehydration, radiation exposure, and biopsy of extra-thyroid neck tissue, which may increase the risk of seeding a possible parathyroid carcinoma.<sup>3</sup>

#### *Implications for Family Members/Reproductive Considerations*

- First-degree relatives (i.e., parents, siblings, and children) have a 50% chance to have the familial *CDC73* mutation. Second-degree relatives (i.e., nieces/nephews, aunts/uncles, and grandparents) have a 25% chance to have the familial mutation.
- For carriers of a known mutation, assisted reproduction (with or without egg or sperm donation), pre-implantation genetic testing, and prenatal diagnosis options exist.
- All family members are encouraged to pursue genetic counseling to clarify their risks. Family members can visit [www.findageneticcounselor.com](http://www.findageneticcounselor.com) to find genetic services near them.

#### **References:**

1. Bricaire L, Odou MF, Cardot-Bauters C, et al. Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. *The Journal of clinical endocrinology and metabolism*. 2013;98(2):E403-408.
2. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. *Nature genetics*. 2002;32(4):676-680.
3. Hyde SM, Rich TA, Waguespack SG, Perrier ND, Hu MI. *CDC73*-Related Disorders. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*((R)). Seattle (WA): University of Washington, Seattle. University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.
4. Iacobone M, Carnaille B, Palazzo FF, Vriens M. Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES). *Langenbeck's archives of surgery*. 2015;400(8):867-886.
5. Bradley KJ, Hobbs MR, Buley ID, et al. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. *Journal of internal medicine*. 2005;257(1):18-26.